Stephen Ansell, MD
Hematology · Rochester, MNNPI 1558335935
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $10,114 of the $10,278 with a category attached, or 98.4%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 98.4% of it on its own, with 1 other manufacturer making up the rest. 2024 is the largest year on record at $10,114, more than ten times the $116 reported in 2022.
Across 11 payments — averaging $934.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$10K
- AstraZeneca$165
Across 198 payments — averaging $26,635 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.3M
- E.r. Squibb & Sons, L.L.C.$1.1M
- Pfizer$1.1M
- Regeneron$603K
- Seagen Inc.$381K
- Astrazeneca UK Limited$227K
- plus $568K from 5 others
What the payments were for
- Travel & lodging$10,11498%
- Food & beverage$1652%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $10,114 |
| AstraZeneca | 6 | $165 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ADCETRIS$10,114
How this compares
$10,278 in reported general payments places this provider in the 70th percentile of 111 hematology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DopteletAvatrombopag Maleate | 11 | $282,080 |
| Acyclovir | 19 | $439 |
Paid to pharmacies, not to this prescriber.
Other hematology in Rochester
- Shaji KumarRochester$452K
- Yi LinRochester$365K
- David DingliRochester$299K
- Morie GertzRochester$261K
- Grzegorz NowakowskiRochester$235K
- Sameer ParikhRochester$151K
- Lindsey RoekerRochester$106K
- Mark LitzowRochester$99K
- Angela DispenzieriRochester$87K
- Prashant KapoorRochester$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.